Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

PrEP news

Show

From To
Council chiefs welcome decision to expand PrEP trial

Local authority leaders have said they are 'pleased' with NHS England's decision to expand the trial of a drug that could 'significantly' reduce levels of HIV.

Published
15 January 2019
From
LocalGov
26% of black MSM in PrEP trial diagnosed with STI during follow-up

More than 26% of black men who have sex with men, or MSM, who were enrolled in a pre-exposure prophylaxis, or PrEP, trial were diagnosed with an STI in follow-up, and younger study participants had higher rates of STIs than older participants, according to research published in Clinical Infectious Diseases.

Published
14 January 2019
From
Healio
NHS hope to double capacity of PrEP trial after huge demand for HIV prevention drug

Deborah Gold, Chief Executive of NAT (National AIDS Trust), said: “Having been pushing for increased access to PrEP for so long, we are pleased that NHS England has listened to us and agreed to fund more spaces for PrEP patients on the Impact trial. It has been completely unacceptable to see people in need of PrEP being turned away from clinics."

Published
11 January 2019
From
National AIDS Trust
Facing Legal Action, Insurer Now Will Cover People Taking Truvada, an H.I.V.-Prevention Drug

Regulators had accused Mutual of Omaha of denying policies to applicants, mostly gay men, who took medication to protect against the infection.

Published
11 January 2019
From
New York Times
NHS England announces support for doubling PrEP trial

NHS England announced on Friday (11 January) its support for a request from researchers leading the PrEP IMPACT Trial. The request asks for the trial to double its places. This would give 26,000 people access to the life-saving pill, compared to the former 13,000 people.

Published
11 January 2019
From
Gay Star News
PrEP: Postcode lottery of anti-HIV drug trial

A game-changer in the fight against HIV, pre-exposure prophylaxis (PrEP) is a highly effective drug that reduces the risk of acquiring the condition. But as the NHS trials PrEP across England, many at high risk have struggled to get hold of the drug.

Published
11 January 2019
From
BBC News
Study Explores Cost-Effectiveness of Conception Strategies for HIV Serodiscordant Couples

A new multi-institutional study has examined the cost-effectiveness of the pre-exposure prophylaxis (PrEP) combination of tenofovir disoproxil fumarate and emtricitabine (TDF/FTC) and assisted reproductive options for serodiscordant couples with an HIV-infected male and HIV-uninfected female looking to conceive. The study focused on examining scenarios in which ‘Undetectable=Untransmittable’ (’U=U’) infection, achieved with combination antiretroviral therapy, (cART) is not sufficient for conception.

Published
09 January 2019
From
Contagion Live
Hep C Infection May Be on the Rise Among Men Using PrEP

The incidence of sexually acquired hepatitis C virus (HCV) infections appears to be rising among men who have sex with men (MSM) and use pre-exposure prophylaxis (PrEP) against HIV, U.S. researchers report.

Published
09 January 2019
From
Medscape (requires free registration)
PrEP home delivery study brings PrEP to young men of color

The small group of young men who took part in a recent PrEP study by a group of California researchers liked being able to access PrEP services and care from the comfort of their own home. The study, called PrEPTECH, offered “telehealth” PrEP care—with clinical visits through a video-based app, home STI testing, and PrEP medication delivered to their doorstep.

Published
08 January 2019
From
BETA blog
HIV rate across Ireland rose by 8% in 2018, figures show

State-funding for HIV prevention drug will bring down diagnoses rate, says HIV activist

Published
07 January 2019
From
Irish Times
← First12345...120Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.